INGELHEIM, Germany & INDIANAPOLIS, US--(BUSINESS WIRE)--A Phase III clinical trial has found that empagliflozin in combination with metformin reduces blood glucose levels in adults with type 2 diabetes (T2D). Boehringer Ingelheim and Eli Lilly and Company presented these findings in a late-breaking poster at the American Diabetes Association’s (ADA) 75th Scientific Sessions®. The 24-week study compared dual therapy of empagliflozin and metformin to monotherapy of either empagliflozin or metformin in patients with T2D.
Help employers find you! Check out all the jobs and post your resume.
